Yuzhou Zhao, Danyang Li, Jing Zhuang, Zhimeng Li, Qingxin Xia, Zhi Li, Juan Yu, Jinbang Wang, Yong Zhang, Ke Li, Shuning Xu, Sen Li, Pengfei Ma, Yanghui Cao, Chenyu Liu, Chunmiao Xu, Zhentian Liu, Jinwang Wei, Chengjuan Zhang, Lei Qiao, Xuan Gao, Zhiguo Hou, Chenxuan Liu, Rongrong Zheng, Du Wang, Ying Liu
BACKGROUND: The current standard of care for locally advanced gastric cancer (GC) involves neoadjuvant chemotherapy followed by radical surgery. Recently, neoadjuvant treatment for this condition has involved the exploration of immunotherapy plus chemotherapy as a potential approach. However, the efficacy remains uncertain. METHODS: A single-arm, phase 2 study was conducted to evaluate the efficacy and tolerability of neoadjuvant camrelizumab combined with mFOLFOX6 and identify potential biomarkers of response through multi-omics analysis in patients with resectable locally advanced GC...
May 2024: Clinical and Translational Medicine